Wayne Pisano, who runs Sanofi-Aventis's vaccine arm, says that the newly acquired Acambis will be kept at arm's length with a minimum of bureaucratic controls to slow it down. But Pisano also conceded that fostering a small-company development mentality in a big pharma subsidiary would prove to be a challenge. But Sanofi definitely plans to grow Acambis. Pisano says he will finance new acquisitions as well as new development work for a general flu vaccines, Japanese encephalitis, West Nile and dengue fever. FierceVaccines